Xphyto Therapeutics

XPhyto Therapeutics (XPHY.C) announced today that it has successfully launched its 25-minute COVID-19 polymerase chain reaction COVID-ID Lab. “The straightforward testing protocol, without prior RNA extraction as part of…
XPhyto Therapeutics (XPHY.C), with its partner and acquisition target, 3a-diagnostics GmbH announced today that it has successfully registered its first biosensor test in oral inflammation with the German authorities….
On July 28, 2021 Xphyto Therapeutics (XPHY.C) announced that its acquisition target, 3a-diagnostics GmbH, has identified the first saliva-activated in-mouth biosensor candidates for the detection of a COVID-19 infection….
XPhyto Therapeutics (XPHY.C) announced today that it has signed a definitive agreement for the acquisition of 3a-Diagnostics GmhB, Frickenhausen, Germany, XPhyto’s exclusive diagnostic development partner.     “We have…
XPhyto Therapeutics (XPHY.C) announced today that its Good Manufacturing Practice (GMP) mescaline synthesis program is on schedule with the completion of initial production batches.   “With both its North…
XPhyto Therapeutics (XPHY.C) has delivered 2,000 of its rapid, 25-minute polymerase chain reaction (PCR) tests, COVID-ID Lab, to an established medical distributor in Israel for clinical evaluation for the…
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports….
“PCR tests are used to directly detect the presence of an antigen, rather than the presence of the body’s immune response, or antibodies,” states Medical Device Network, “By detecting…
The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports….
Xphyto Therapeutics (XPHY.C) subsidiary Xphyto Laboratories added mescaline to its list of psychedelic medicine programs today, according to a press release. Earlier this month the company brought Applied Pharmaceutical…